










Improved detection of blood stream pathogens
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of the technical and diagnostic feasi-
bility of commercial multiplex real-
time polymerase chain reaction
(PCR) for detection of blood stream
infections in a cohort of intensive
care unit (ICU) patients with severe
sepsis, performed in addition to con-
ventional blood cultures.
Design: Dual-center cohort study.
Setting: Surgical ICU of two uni-
versity hospitals. Patients and
participants: One hundred eight
critically ill patients fulfilling the
American College of Chest Physi-
cians/Society of Critical Care
Medicine (ACCP/SCCM) severe
sepsis criteria were included. Inter-
ventions: None. Measurements and
results: PCR results obtained in 453
blood samples from 108 patients were
compared with corresponding blood
culture results. PCR resulted in a
twofold higher positivity rate when
compared with conventional blood
culture (BC) testing (114 versus 58
positive samples). In 40 out of 58
PCR positive assays the results of the
corresponding blood cultures were
identical to microorganisms detected
by PCR. In 18 samples PCR and BC
yielded discrepant results. Compared
with conventional blood culture the
sensitivity and specificity of PCR was
0.69 and 0.81, respectively. Further
evaluation of PCR results against a
constructed gold standard including
conventional microbiological test
results from other significant patient
specimen (such as bronchio-alveolar
lavage fluid, urine, swabs) and addi-
tionally generated clinical and
laboratory information yielded sensi-
tivity of 0.83 and specificity of 0.93.
Conclusions: Our cohort study
demonstrates improved pathogen
detection using PCR findings in
addition to conventional blood culture
testing. PCR testing provides
increased sensitivity of blood stream
infection. Studies addressing utility
including therapeutic decision-mak-
ing, outcome, and cost-benefit
following diagnostic application of
PCR tests are needed to further assess
its value in the clinical setting.
Keywords Detection of blood stream
pathogens  Real-time PCR 
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Introduction
Sepsis is the second leading cause of death in the non-
coronary ICU. Sepsis is associated with mortality rates
ranging from 20% to 50% [1, 2]. Early diagnosis followed
by prompt appropriate treatment [3] improves the prog-
nosis of septic patients [4, 5]. One important therapeutical
aspect is early initiation of calculated antibiotic therapy.
Each hour of delay in administration of antibiotics is
associated with an average 8% decrease in survival rate of
septic shock [6]. Blood cultures (BC) must be obtained
before antibiotic therapy [3] which should be reassessed
on the basis of culture results and clinical data [7]. Timely
and continuous reassessment is important, since inap-
propriate antibiotic therapy deteriorates outcome [8, 9],
whereas adequate therapy is associated with favorable
outcome [10, 11].
Typically, BC specimens become positive within
24–36 h after sampling and therapy can be optimized
based on presumptive bacterial identification. A complete
microbial identification and susceptibility profile, how-
ever, is usually not available before 24–72 h later. Despite
advances in BC techniques [12, 13] BC positivity rates
remain low and may vary significantly, depending on
severity of sepsis and ongoing antibiotic treatment
[14–16]. It has been suggested that nucleic-acid-based
technology such as PCR is more sensitive and can also
shorten the time to result when compared with conven-
tional BC technique [17]. The development and initial
evaluation of such an assay was recently reported
[18, 19]. Our study objective was to evaluate the technical
and diagnostic feasibility of a commercial multiplex real-
time PCR-based method for diagnosis of blood stream
infections in a cohort of ICU patients with severe sepsis.
Under the conditions of this investigation PCR was used
in addition to conventional BC diagnostics as performed
according to the local standard procedures of the partic-
ipating centers. Primary endpoint of this study was the
positivity of findings for microbial DNA in relation to
results from conventional microbiological testing of
patients with severe sepsis. Secondary endpoints were
differences of Sequential Organ Failure Assessment
(SOFA) score, procalcitonin (PCT) and interleukin (IL)-6




This study was performed in patients from two surgical
ICUs, including a total of 108 patients, covering a total of
453 paired blood samples, consisting of simultaneously
obtained BC and PCR blood samples. The relevant
institutional or regional review boards or ethics commit-
tees approved the research protocol and participants or
legal guardians gave written informed consent. All
patients included were clinically suspected of suffering
from severe sepsis of bacterial or fungal origin. Severe
sepsis was classified according to the ACCP/SCCM con-
sensus conference criteria of 1998 [14]. Inclusion followed
after independent decision of the physician in charge to
call for a blood culture. Repeated samples per patient were
allowed. The Systemic Inflammatory Response Syndrome
(SIRS) criteria [temperature, heart rate, respiratory rate,
and white blood cell (WBC) count] were obtained for all
patients. Further data were compiled regarding antibiotic
regimen, site of infection, SOFA score (degree of organ
dysfunction), procalcitonin (PCT) and interleukin-6 (IL-6)
plasma level, length of stay (ICU and hospital), and hos-
pital survival. Following the prospective and observational
study design, physicians in charge did not use PCR test
results to guide clinical treatment.
BC procedures and blood collection for the PCR test
Twenty microliters whole blood, freshly drawn according
to common standards of the German Society of Medical
Microbiology and Hygiene (DGHM) [20], were used for a
pair of aerobic/anaerobic BC bottles (BACTEC, Becton
Dickinson GmbH, Germany). Immediately after drawing
blood for culture, 9 ml whole blood was then collected
in sterile MONOVETTE ethylenediamine tetraacetic
acid (EDTA) K2E tubes (Sarstedt, Germany) for further
analysis by PCR test. All BC were processed using semi-
automated BC systems (BACTEC 9240, Becton Dickin-
son GmbH, Germany) according to the manufacturer’s
instructions and the published standards of the DGHM
[20]. The BC system and the local laboratory software
automatically registered time to positive BC.
Sample preparation and PCR procedure
Preparation of DNA and PCR testing was performed from
1 ml whole blood samples using the SeptiFast Lys Kit,
the SeptiFast Prep Kit and the LightCycler SeptiFast
Kit as described recently in more detail [18]. In brief,
samples were mechanically lyzed and internal controls
(IC) were included in each sample and in negative con-
trols (NC). Manual extraction was performed to obtain a
final extraction volume of 200 ll DNA. Eluate (50 ll)
was used for subsequent real-time PCR amplification
using the LightCycler 2.0 Instrument. Potential contami-
nations were eliminated using uracil-N-glycosylase. DNA
amplification targets were conserved and variable parts of
the internal transcribed sequence (ITS) regions of bacteria
and fungi [18]. Amplified variable parts of any amplifi-
cation products were then hybridized to genus- or species-
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specific oligonucleotide probes and subjected to software-
assisted temperature melting-peak (Tm) analysis using the
SeptiFast Software set V2.0 (Roche Diagnostics GmbH,
Penzberg, Germany) to reliably identify microorganisms
covered by the SeptiFast test panel [18]. A result was
regarded as a true negative only if included ICs were
measured positive. Moreover, the assay was regarded as
valid only if the NC tested negative and the corresponding
controls (reagent control and the IC of the NC) were
detected within their assigned Tm ranges. According to
recent study data, time to report for the method’s work-
flow is less then 6 h and the analytical sensitivity of the
assay ranges between 3 and 100 CFU/ml, depending on
the individual microorganism [18].
Comparison of LightCycler SeptiFast test results
with BC findings
A blood stream infection was defined as a positive BC
result, obtained and analyzed as set forth by the current
DGHM procedures [20]. Interpretation of BC findings
was performed according to established clinical and
microbiological standards (DGHM) [20]. Whether
microorganisms identified by PCR represented true
infection or contamination was evaluated retrospectively
by taking into account the identity of the microorganism
detected and by comparing PCR results with corre-
sponding BC findings. For common facultative and
obligate bacterial pathogens except potential skin con-
taminants such as coagulase-negative Staphylococcus
(CoNS) and some streptococcal species, a positive BC
result was interpreted as evidence for ongoing blood
stream infection (BSI). For CoNS and streptococci,
positive BC results were interpreted as evidence for BSI
only if BC demonstrated growth of identical organisms in
two or more different samples of a given patient within
72 h. If a single positive result was reported for these
microorganisms within a 72-h period the results were
interpreted as probable contamination. Purpose of this
study was primarily to evaluate the technical and diag-
nostic feasibility of PCR as an add-on to conventional BC
diagnostics as routinely performed in the participating
centers, no 24-h 7-days-a-week PCR service was provided
throughout the investigation. Therefore, direct compari-
son of ‘‘time-to-result’’ performance between PCR and
conventional blood culture methods is not part of the
analysis as presented in this study.
Analysis of clinical data in conjunction with PCR
and BC findings
Sepsis patients were grouped according to BC and PCR
results obtained during the patient’s individual course.
Negative findings throughout the clinical course by both
BC and PCR led to inclusion in the PCR negative/BC
negative group, positive findings by BC and PCR led to
inclusion in the PCR positive/BC positive group,
respectively. Single positive results for PCR without
corresponding BC culture findings throughout the entire
course led to inclusion in the PCR positive/BC negative
group. Conversely, negative PCR and positive BC were
grouped as PCR negative/BC positive. Maximum PCT
level and SOFA score, and length of ICU and hospital
stay for each patient’s course, as well as patient survival
were also recorded for this analysis.
Comparison of LightCycler SeptiFast test results
with a constructed gold standard
In the course of microbiological screening for potential
infectious foci in the individuals with severe sepsis
additional microbiological samples were taken from var-
ious body sites and subjected to conventional culture and
additional microbiological testing. For assessment of the
diagnostic plausibility of available PCR results, the status
of infection in the sepsis cohort was further analyzed in
the light of a constructed gold standard generated from
such supplementary data from additional microbiological
samples. For this in-depth analysis a positive PCR result
from the patient’s blood was regarded as a true positive
only if the detected microorganisms were present also in
the corresponding BC and/or in other supplementary
materials of the patient expected to be sterile under
healthy conditions (i.e., bronchio-alveolar lavage fluid,
intra-abdominal swabs, urine, etc.) obtained ±2 days
from the onset of the septic episode.
Statistical methods
Comparisons were made by 2 9 2 contingency tables.
Differences between groups were analyzed by one-way
analysis of variance (ANOVA) using the GraphPad Prizm
4.0 statistical software package.
Results
Study and control population characteristics
A total of 108 patients with severe sepsis from the two
study sites were included in the study. All patients were
under antibiotic coverage at the beginning and throughout
the observational study. The corresponding demographics
are depicted in Table 1. The most common underling
causes of severe sepsis were peritonitis, pneumonia, and
severe sepsis following cardiovascular surgery (Table 1).
Most frequent comorbidities were chronic renal failure
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and New York Heart Association class III or IV heart
failure (Table 2).
Analysis of PCR compared with BC
PCR results of 453 blood samples were compared with
the results of conventional BC that had been obtained in
parallel at each individual time point of sampling. In
septic patients, BC were positive in 58 samples (12.8%).
In the concomitantly drawn EDTA blood samples PCR
yielded 114 positive results (25.2%; Table 3). PCR thus
resulted in a twofold higher recovery rate compared with
conventional BC (Fig. 1a). Of 58 positive BC findings, 40
corresponded directly to the PCR test results. Based on
this, the negative predictive value of PCR versus blood
culture as a gold standard was 0.95, sensitivity was 0.69,
and specificity was 0.81. However, 18 samples of positive
BC showed different PCR results.
Analysis of discrepancies
Thirteen out of 18 discrepant cases (72%) could be
resolved either by not being in the panel covered by PCR
such as Pantoea agglomerans (n = 4) and Proprioni-
bacterium spp. (n = 2), or because they were judged as
contaminating skin flora (n = 7; Table 3). However, five
positive BC yielding growth of Serratia marcescens
(n = 1), Enterococcus faecalis (n = 1), Enterococcus
faecium (n = 2), and Candida glabrata (n = 1) did not
match the corresponding PCR result (Table 3). Despite
evidence of real infection as judged by independent
clinical review the negative PCR finding remained
unresolved.
Analysis of PCR results versus a constructed gold
standard
PCR results were also analyzed against a constructed
microbiological gold standard. This constructed gold
standard included BC findings and/or additional micro-
biological test results from other patient materials
expected to be sterile under healthy conditions and
obtained ±2 days from onset of the corresponding septic
episode. The rationale for introducing such a constructed
gold standard was to further elucidate the plausibility of
the unopposed positive PCR. PCR detected 74 pathogens
which were not confirmed by the corresponding BC
Table 1 Characteristics and causes of sepsis of the study patients
All Female Male
Patients (n) 108 36 72
Age, mean (range), years 58.37 (18–84) 60.10 (19–84) 57.42 (18–84)
Survival (n) 65 (60%) 25 (69%) 40 (56%)
Nonsurvival (n) 43 (40%) 11 (31%) 32 (44%)
Underlying cause of sepsis Number
Abdominal sepsis (peritonitis, necrotizing pancreatitis,
cholangitis or cholecystitis)
35
Sepsis following cardiovascular surgery 28
Pneumonia/ARDS 23






Table 2 Chronic comorbidities of study patients (n = 108)
No.a Total (%)a
Neoplasms (acute or chronic lymphoma, acute or chronic leukemia, metastatic solid cancer) 20 18.5
Liver failure (biopsy-proven cirrhosis, documented variceal hemorrhage or
portal hypertension, hepatic ascites or hepatic encephalopathy)
18 16.7
New York Heart Association class III or IV heart failure 55 50.9
Chronic renal failure (serum creatinine [1.5 of upper normal limit) or renal replacement therapy 49 45.4
Diabetes mellitus (non-insulin-dependent and insulin-dependent) 21 19.4
a Patients (n = 108) presented multiple comorbidities. Sums of individual comorbidities (n = 163) and relative comorbidity fractions of
the whole study population are given
52
analysis. However 51 of these 74 PCR results matched
microbiological test results from additional specimens.
These additional results included detection of Entero-
bacter cloacae/aerogenes (n = 6), Escherichia coli
(n = 5), Klebsiella oxytoca/pneumoniae (n = 7), Proteus
mirabilis (n = 1), Pseudomonas aeruginosa (n = 5),
Serratia marcescens (n = 1), Stenotrophomonas malto-
philia (n = 1), Enterococcus faecalis (n = 6), Entero-
coccus faecium (n = 8), Staphylococcus aureus (n = 3),
Streptococcus spp. (n = 1), Aspergillus fumigatus
(n = 4), and Candida albicans (n = 2) by both PCR and
conventional culture from primarily sterile body materials
other than blood (Table 3). When compared with the
constructed gold standard the sensitivity of PCR increased
to 0.83, the specificity increased to 0.93, and the negative
predictive value to 0.95.
Analysis of the clinical course of the study population
The 108 sepsis patients were grouped according to
matching results of BC and PCR results during their
clinical course. Positive BC findings with concomitant
positive PCR results (n = 40 samples) were present in 16
out of 108 patients during the septic episode. PCT plasma
level, SOFA score, length of ICU, and hospital stay in
these patients were significantly increased, while survival
was decreased, when compared with the 66 patients of the
cohort with negative findings in 321 BC and parallel PCR
samples (p \ 0.05; Table 4).
Discussion
In this observational study we investigated the imple-
mentation and potential add-on utility of a new PCR test
compared with conventional BC diagnostics. To date, BC
still play a pivotal role in the diagnosis of sepsis and are
regarded as the microbiological gold standard for the
detection of bloodstream infections in patients with clinical
sepsis and fever of unknown origin [17]. The practical
value of BC in the diagnosis of sepsis, however, is clearly
impaired due to lengthy detection time. Commonly the
positive yield does not exceed 5–30% in septic patients,
mainly depending on the severity of the disease and
localization of the infection [21]. Likewise, the sensitivity
of BC is known to be poor for many slow-growing and
fastidious organisms [22]. As shown in this study PCR-
based assay technology holds promise to circumvent some
methodological drawbacks of conventional culture and to
enhance detection of bacteria and fungi in patients with
suspected sepsis. Compared with conventional BC diag-
nostics, PCR testing resulted in a twofold higher positivity
Table 3 Microbiological findings by blood culture and PCR
Gram-negative organisms BC only BC ? PCR PCR only PCR ? suppl. cultures
Enterobacter cloacae or aerogenes 0 7 13a 6
Escherichia coli 0 3 16 5
Klebsiella oxytoca or pneumoniae 0 1 14a 7
Pantoea agglomerans 4 Not in panel Not in panel 0
Proprionibacterium spp. 2 Not in panel Not in panel 0
Proteus mirabilis 0 0 1 1
Pseudomonas aeruginosa 0 1 6 5
Serratia marcescens 1 1 5 1
Stenotrophomonas maltophilia 0 2 3 1
Gram-positive organisms BC only BC ? PCR PCR only PCR ? MiBi
Coagulase-negative Staphylococci 7b 7 12c 0
Enterococcus faecalis 1 8 15 6
Enterococcus faecium 2 2 10 8
Staphylococcus aureus 0 5 8 3
Streptococcus spp. 0 0 1 1
Yeast/fungi BC BC ? PCR PCR PCR ? MiBi
Aspergillus fumigatus 0 0 4 4
Candida albicans 0 3 5 2
Candida crusei 0 0 1 0
Candida glabrata 1 0 0 0P
of all 18 40 114 51
a Indistinguishable for PCR method due to ITS-sequence homol-
ogies between E. cloacae and E. aerogenes, and between
K. oxytoca and K. pneumoniae, respectively
b samples of coagulase-negative Staphylococci were regarded as
contamination
c Seven further positive PCR results were regarded as contamina-
tion and not included
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rate in our cohort of patients with clinical sepsis (Fig. 1a).
To further investigate the clinical plausibility of PCR
results, we also included additional laboratory data and
culture results obtained from additional body sites that
were clinically incriminated to be focus of ongoing infec-
tion in these patients (constructed gold standard, Fig. 1b).
Interestingly, in 51 of 74 conventional samples (69%) the
additional microbiological findings paralleled the PCR
results obtained directly from the blood of the corre-
sponding patients (Fig. 1b) and, thus, may be interpreted as
an important additional clue for the involvement of the
recovered microorganisms in the ongoing septic infection
in these individuals. Finally, the remaining 23 PCR-posi-
tive but discrepant constructed gold standard-negative
samples remain unresolved at this point. Such inconclusive
results may be interpreted as being either false-positive
PCR assays or false-negative constructed gold standard
findings. False-positive PCR results, however, may also
originate from the amplification of free DNA released from
nonviable or killed bacteria and fungi, thereby mimicking
ongoing infection. Future interventional trials utilizing
PCR-guided therapy may enlighten the relevance of PCR-
positive but BC (or constructed gold standard) negative
findings in the clinical context of the ICU.
Timely and adequate antimicrobial treatment is key
for improved outcome in patients with pneumonia, men-
ingitis, and sepsis [8, 23]. Recently Kumar et al. showed
that from the onset of hypotension in patients presenting
with septic shock, each hour of delay in adequate anti-
microbial treatment on average was associated with 8%
decrease in survival rate [6]. Similarly, improved survival
in sepsis patients with early adequate therapy has been
demonstrated in several other studies [4, 9–11]. The
diagnosis of bacteraemia by BC, however, can be delayed
for 12–48 h even in common rapid growers depending on
individual growth kinetics and initial inoculum, thereby
complicating a more timely diagnosis in patients with
sepsis. Moreover, the recovery rate of conventional cul-
tures is clearly impaired after initiation of antimicrobial
treatment despite current BC systems having been mod-
ified in an attempt to reduce the effect of antimicrobials in
the BC bottle [24]. Although a comparative time-to-result
analysis of PCR and BC was not part of this study, the
given turnaround time of 6 h for the PCR assay [18] may
turn out to be an important add-on of PCR technology
compared with the 12–48 h time interval necessary to
generate initial BC findings [25, 26]. Another possible
advantage of a DNA-based detection system is that the
microorganisms causing sepsis do not have to be viable at
the time of sampling, thereby also including phagocytized
or partly digested bacteria within white blood cells. Thus,
PCR may be advantageous particularly in patients
receiving antibiotics.
Clearly, little is known about the kinetics and clinical
and therapeutic relevance of bacterial DNA present in the
blood of patients with sepsis over time in the course of an
invasive blood stream infection. The potential influence
of circulating bacterial DNA on the severity and outcome
of blood stream infections, however, is underlined by the
findings of our study demonstrating that PCT plasma
levels and SOFA scores were significantly higher, length
of ICU and hospital stay were longer, and survival was
A Sepsis cohort (n=108)  




Positive 40 74 114 
Negative 18 321 339 
58 395 453 
B Sepsis cohort (n=108)  
PC
R 
Constructed Gold Standard 
Positive Negative 
Positive 91 23 114 
Negative  18 321 339 
 109  334  453 
Fig. 1 a Analysis of PCR results compared with BC findings in
sepsis patients (study group). b Analysis of PCR results compared
with a constructed gold standard, comprising positive BC findings
or detected organisms in additional patient specimen (e.g., bron-
chio-alveolo lavage, urine, swabs)












PCR-/BC- (n = 66) 1.7 (0–56.0) 11 (2–20) 17 (1–89) 23 (1–93) 66 \0.05
PCR?/BC? (n = 16) 12.1 (0.4–139.9) 16 (12–20) 36 (8–87) 38 (8–90) 33
LOS-ICU length of stay on ICU, LOS hospital length of stay in hospital
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clearly decreased in a subgroup of patients revealing
positive findings in both PCR testing and BC.
Although rapid and specific, an important limitation
of the current PCR assay, however, arises from the fact
that some pathogens that are not part of the detection
panel, such as Pantoea agglomerans and Proprionibac-
terium spp., were missed by PCR but recovered by BC.
In five other cases microorganisms that are part of the
PCR detection panel were not detected by PCR but
were detected in BC. These cases comprised Serratia
marcescens (n = 1), Enterococcus faecalis (n = 1),
Enterococcus faecium (n = 2), and Candida glabrata
(n = 1). Of note, all bacterial isolates in the BC became
positive after prolonged culture periods, clearly pointing
to a low-level in vivo bacteraemia at the time point of
sampling. The results of quantitative BC studies have
shown that most episodes of clinically significant bac-
teraemia in adults are characterized by low numbers of
circulating bacteria. Werner et al. found that 54% of BC
from adult patients with staphylococcal and streptococ-
cal endocarditis contained between 1 and 30 CFU/ml of
blood [27]. Moreover, Kreger et al. described that 73%
of 77 patients with Gram-negative bacteremia had BC
that contained \10 CFU/ml of blood [28]. An analytical
assay sensitivity of 3–30 CFU/ml [18] and a predefined
detection panel of 25 different BSI pathogens, thus, limit
to some extent the diagnostic capabilities of the current
assay in patients with sepsis when compared with a
theoretical sensitivity of one CFU per culture bottle in
conventional blood culture after inoculating *10 ml
whole blood. Increasing the starting volume of the PCR
test may help to increase the stochastic probability of
picking up a pathogen in cases of low-level bacteraemia.
In addition, the current test could be improved by adding
an additional assay component for the detection of
consensus DNA of bacteria or fungi, thereby providing
identification of pathogens which are not primarily part
of the PCR panel. The feasibility of assays diagnosing
bacteria and fungi by consensus DNA detection has been
described previously [29].
Summing up, the novel PCR-based assay system, at
present, cannot fully substitute conventional BC also
because a more general susceptibility testing of the recov-
ered organisms is not yet possible. Nevertheless, the
clinical value of classical BC techniques was also clearly
impaired, in part due to the low recovery rate in our sepsis
cohort. Moreover, BC show a prolonged time-to-result
interval, as it usually takes at least 12–48 h to provide the
clinician with Gram stain results and species identification.
As shown in the present study, novel real-time PCR-
based molecular biological assays for rapid detection of
important pathogens causing BSI can overcome some
limitations of the conventional culture-based microbio-
logical techniques, especially when it comes to more
rapid detection and species identification of blood stream
pathogens. As such, molecular test systems may be seen
as a valuable add-on, providing important additional
information to the treating physicians very early in the
course of disease, thereby potentially tailoring the anti-
biotic coverage in septic patients. Whether the assay will
indeed significantly contribute to more rapid initiation of
better-tailored antimicrobial therapy and improved patient
management in conjunction with other laboratory mark-
ers, however, awaits further evaluation of the test in
interventional clinical studies.
Conclusions
Our study demonstrates good concordance of PCR results
with BC. Moreover, we confirmed the increased sensi-
tivity of PCR-based detection of bloodstream infections,
as shown in other studies. These results are indicative of
potential clinical utility of PCR-based pathogen identifi-
cation in patients with severe sepsis. Studies addressing
changes in clinical decision-making, outcome, and cost-
benefit by the utilization of PCR results, however, are
needed.
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